Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Nathan

Showing results (121-130 of 129) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 129 results.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2024
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024Claus Garbe, Teresa Amaral, Ketty Peris, et al.
The New England Journal of Medicine|September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Journal for Immunotherapy of Cancer|April 23, 2020
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanomaJonathan S Cebon, Martin Gore, John F Thompson, et al.
The Lancet. Oncology|August 21, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trialRobert J Motzer, Brian I Rini, David F McDermott, et al.
Nature Medicine|March 1, 2022
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanomaKarla A Lee, Andrew Maltez Thomas, Laura A Bolte, et al.
Nature Medicine|February 16, 2024
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanomaJohannes R Björk, Laura A Bolte, Andrew Maltez Thomas, et al.
Pediatric Blood & Cancer|March 27, 2026
Novel Genetic Risk Factor Identified for L-Asparaginase-Induced Pancreatitis in Pediatric Patients With CancerEdward J Raack, Wan-Chun Chang, Miguel Cordova-Delgado, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastasesMario Mandalà, Monica F Chen, Ryan J Sullivan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialP G Corrie, A Marshall, P D Nathan, et al.
Pageof 13

Showing results (121-130 of 129) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 129 results.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2024
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024Claus Garbe, Teresa Amaral, Ketty Peris, et al.
The New England Journal of Medicine|September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaGeorgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Journal for Immunotherapy of Cancer|April 23, 2020
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanomaJonathan S Cebon, Martin Gore, John F Thompson, et al.
The Lancet. Oncology|August 21, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trialRobert J Motzer, Brian I Rini, David F McDermott, et al.
Nature Medicine|March 1, 2022
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanomaKarla A Lee, Andrew Maltez Thomas, Laura A Bolte, et al.
Nature Medicine|February 16, 2024
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanomaJohannes R Björk, Laura A Bolte, Andrew Maltez Thomas, et al.
Pediatric Blood & Cancer|March 27, 2026
Novel Genetic Risk Factor Identified for L-Asparaginase-Induced Pancreatitis in Pediatric Patients With CancerEdward J Raack, Wan-Chun Chang, Miguel Cordova-Delgado, et al.
Journal for Immunotherapy of Cancer|May 4, 2026
Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastasesMario Mandalà, Monica F Chen, Ryan J Sullivan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trialP G Corrie, A Marshall, P D Nathan, et al.
Pageof 13